Inclusion Criteria:

- Histological or cytological confirmation of a solid, malignant tumour that is
refractory to standard therapies or for which no standard therapies exist

- At least one lesion (measurable and/or non-measurable) that can be accurately
assessed at baseline by computerised tomography (CT) magnetic resonance imaging (MRI)
or plain X-ray and is suitable for repeated assessment

- World Health Organisation performance status 0-2 with no deterioration over the
previous 2 weeks and minimum life expectancy of 12 weeks

Exclusion Criteria:

- Patients with severe laboratory abnormalities for haematology, liver or renal
function. Also treatment with any haemopoietic growth factors are not allowed within
two weeks from first dose of study drug

- Patients with abnormal fasting glucose, type I or uncontrolled type II diabetes

- Patients with severe cardiac condition of ischemia, impaired ventricular function and
arrhythmias, evidence of severe or uncontrolled systemic or current unstable or
uncompensated respiratory or cardiac conditions